Grace Therapeutics, Inc.

What they do

Grace Therapeutics develops reformulated versions of approved drugs for rare and orphan diseases using proprietary drug delivery technologies. Its pipeline includes three clinical-stage candidates, with lead candidate GTx-104 being an IV formulation of nimodipine for aSAH patients. The company relies on the FDA's 505(b)(2) regulatory pathway and has orphan drug designations for all candidates.

Revenue drivers

• No commercial products — The company has no approved products and no recurring revenue; historical revenue figures were nominal (e.g., $196,000 in 2021).
• GTx-104 (lead candidate) — Primary value driver; an injectable nimodipine for aSAH, undergoing NDA resubmission after a CRL; potential NDA fee waiver of ~$4.3 million and seven-year orphan drug exclusivity if approved.
• GTx-101 and GTx-102 (deprioritized) — De-prioritized since 2023; fully impaired in Q1 2027; potential value only through out-licensing or sale.

Recent performance

For the quarter ended June 30, 2026, the company reported a net loss of $15.8 million, or $0.91 per share, compared to a $3.4 million loss ($0.21 per share) in the year-ago quarter. The increase was driven by a $13.5 million impairment of IPR&D related to GTx-101 and GTx-102. Cash used in operations was about $3.2 million. Cash and equivalents stood at $13.8 million as of June 30, 2026, down from $17.0 million at March 31, 2026. Total assets were $50.1 million, with shareholder equity of $48.2 million.

Strategy

Management is executing a dual-source manufacturing strategy for GTx-104 to mitigate CRL-related remediation risks. They are working with the current contract manufacturer to resolve FDA cGMP deficiencies while also advancing a technology transfer to a second, U.S.-based manufacturer. NDA resubmission timing will depend on which site reaches readiness first. The company completed a $10 million private placement in August 2026 to fund manufacturing and regulatory work, extending cash runway through end of calendar 2028.

Risks

• CRL delays GTx-104 approval — FDA's April 2026 CRL cited manufacturing deficiencies and non-clinical issues, which may delay or prevent NDA approval.
• Dependence on CMO remediation — The current CMO must fix cGMP deficiencies, and failure could force a costly, time-consuming transfer to an alternative facility.
• No commercialization experience — The company has not commercialized any product, and may lack the infrastructure to market GTx-104 if approved.
• Heavy dependence on a single candidate — GTx-104 is the lead and only actively pursued candidate; GTx-101 and GTx-102 are deprioritized and impaired, leaving little pipeline diversity.

Outlook

Management plans to resubmit the NDA for GTx-104 after addressing CRL items, including additional leachables data, toxicology risk assessments, and CMO remediation. They expect to complete the required 12-month stability program for the second manufacturing site if that route is needed. The company aims to achieve NDA resubmission as soon as either manufacturing site is ready, with no timeline provided. Cash runway is expected to extend through the end of calendar 2028.